Expanded access program (EAP) to investigational drugs

Reviewer: Maria Luisa Veronese, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 6 de junio del 2004

Translation for this article does not exist


Catherine and Finn
by OncoLink Editorial Team
December 01, 2015

Related News

FDA Approves Expanded Use for Melanoma Drug

Oct 30, 2015

Yervoy can now be used after surgery to reduce risk of skin cancer returning

FDA Expands Imbruvica Approval to Include CLL

Feb 14, 2014

Approval of Imbruvica (ibrutinib) expanded to include people with chronic lymphocytic leukemia

FDA: Opdivo Approval Expanded to Include Lung Cancer

Mar 5, 2015

FDA approves drug for NSCLC patients who have been treated with platinum-based chemotherapy